Meag Munich Ergo’s BeOne Medicines Ltd ONC Stock Holding History

Meag Munich Ergo’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-3,600	Closed	-$485K	–	230
2022 Q3	$485K	Buy	+3,600	New	+$618K	0.03%	177
2022 Q2	–	Sell	-700	Closed	-$134K	–	236
2022 Q1	$134K	Sell	700 -6,500	-90%	-$1.38M	0.01%	190
2021 Q4	$1.98M	Hold	7,200	–	–	0.14%	94
2021 Q3	$2.61M	Hold	7,200	–	–	0.45%	63
2021 Q2	$2.47M	Buy	7,200 +2,100	+41%	+$696K	0.24%	106
2021 Q1	$1.77M	Buy	5,100 +3,900	+325%	+$1.29M	0.18%	131
2020 Q4	$306K	Sell	1,200 -2,500	-68%	-$688K	0.07%	175
2020 Q3	$1.06M	Hold	3,700	–	–	0.2%	116
2020 Q2	$697K	Hold	3,700	–	–	0.13%	146
2020 Q1	$456K	Sell	3,700 -22,000	-86%	-$3.44M	0.11%	126
2019 Q4	$4.28M	Buy	25,700 +3,600	+16%	+$598K	0.46%	54
2019 Q3	$2.68M	Hold	22,100	–	–	0.14%	172
2019 Q2	$2.78M	Hold	22,100	–	–	0.22%	106
2019 Q1	$2.79M	Hold	22,100	–	–	0.23%	98
2018 Q4	$3.06M	Buy	+22,100	New	+$2.93M	0.38%	69

Other funds holding ONC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

CII

Capital International Inc Los Angeles, California $14.3B AUM 34.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Meag Munich Ergo's ONC Position: Q4 2022 in Review

Meag Munich Ergo sold out of BeOne Medicines Ltd (ONC) in Q4 2022, closing a stake of 3,600 shares — an estimated $485K sold.

Meag Munich Ergo first reported a position in ONC in Q4 2018 and held it in 15 quarters. The position peaked at $4.28M in Q4 2019. 212 funds tracked by Wall St. Rank hold ONC as of Q4 2022.

Meag Munich Ergo reported no remaining BeOne Medicines Ltd position as of Q4 2022 after selling out during the quarter.
Meag Munich Ergo sold 3,600 BeOne Medicines Ltd shares in Q4 2022, an estimated $485K.
Meag Munich Ergo first reported a position in BeOne Medicines Ltd in Q4 2018 and held it in 15 quarters.
Meag Munich Ergo's BeOne Medicines Ltd position peaked at $4.28M in Q4 2019.
212 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q4 2022.

Based on Meag Munich Ergo's 13F filing for Q4 2022, filed 19 Jan 2023.